Morning trading May 10, page-215

PTX
Ann. treating leukemia
Very rare to get such break throughs
This will get some action very soon imo

"The study’s Principal Investigator, Professor Lancet, said, “It is encouraging to see a CRi at this dose level, which brings a total of four complete remissions on the study so far. It was also pleasing to see that this dose level was well tolerated by patients, with no reported dose-limiting toxicities."